⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 3, 2017The LancetOpen Access

Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial

Julia Prague Rachel Roberts Alexander Comninos Sophie Clarke Channa Jayasena Zachary Nash Chedie Doyle Deborah Papadopoulou Stephen R. Bloom Pharis Mohideen Nicholas Panay Myra S. Hunter Johannes D. Veldhuis Lorraine Webber Les Huson Waljit S. Dhillo

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

UK Medical Research Council and National Institute for Health Research.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Prague et al. (2017) studied this question.

synapsesocial.com/papers/69dcc97a7873f5f05b134160 https://doi.org/10.1016/s0140-6736(17)30823-1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Duration of Menopausal Vasomotor Symptoms Over the Menopause TransitionCohort Study · 2015 · 1,034 citations
2MsFLASH participants’ priorities for alleviating menopausal symptomsCross-Sectional Study · 2015 · 46 citations
3Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studiesRisk Assessment · 2015 · 472 citations
4A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patientsSystematic Review · 2015 · 80 citations
5Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2)RCT · 2012 · 208 citations

Use of Plant-Based Therapies and Menopausal Symptoms2016
Methodologic Lessons Learned From Hot Flash Studies2001
Miniature ambulatory skin conductance monitor and algorithm for investigating hot flash events2014
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trialThe Lancet · 2019
Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trialThe Lancet · 2020

More from The Lancet